Latest Anemia News
New study shows that IV iron repletion with sodium ferric gluconate complex increased platelet count significantly at week 3 post-infusion and non-significantly at week 4.
Clinicians should advise women who could become pregnant to use effective contraception before and after taking the anemia drug.
In a study, use of anticoagulants was associated with 85% fewer atherosclerotic events.
In a trial, oral calcitriol of 0.5 mcg daily did not reduce hepcidin levels in patients with stage 3 to 4 CKD.
Dialysis patients receiving more or less than 200 mg per month of IV iron had similar risks of death, infection, cardiovascular disease, and hospitalization, meta-analysis shows.
The Food and Drug Administration broadened the existing labeling for Feraheme (ferumoxytol injection) beyond the current chronic kidney disease indication.
In a 52-week trial, more than half of nondialysis-dependent chronic kidney disease patients with anemia treated with oral iron had no rise in their hemoglobin levels.
Patients with hemoglobin values of 9.7 g/dL or below had more than double the risk for hemorrhagic stroke compared with patients with hemoglobin values of 11.2 g/dL or above.
The safety profile of CERA is similar for children as for adults.
To support ESA therapy, IV iron at doses below 300 mg/month may be most effective for the average hemodialysis patient, according to an observational study.
Urinary ceruloplamin has potential to be a chronic kidney disease biomarker for patients with sickle cell anemia.
Researchers tested once weekly and biweekly administration of darbepoetin alfa in children aged 1 to 18 years not previously treated with an erythropoiesis-stimulating agent.
Researchers find no significant difference in the median erythropoietin resistance index between patients with versus without residual renal function.
To shed light on the often-challenging management of this common condition, a case of a hypothetical patient was presented to a doctor who specializes in advanced heart failure and transplant cardiology.
High doses of iron are associated with a significantly higher risk of cardiovascular disease, regardless of the dose of erythropoiesis-stimulating agent.